Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072226 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase 3 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 3
- Development phase
- 313
- Enrollment target
NCT02072226 is a Phase 3 study that was terminated before completion, run by Genentech. The registered enrollment target is 313 participants.
The verdict
NCT02072226, a Phase 3 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 313 participants
- Enrollment target
Study Summary
PRISMS is a double-blind, multicenter, randomized, Phase IIIb study to evaluate the efficacy and safety of intravenous (IV) alteplase in participants with mild acute ischemic strokes that do not appear to be clearly disabling. Participants will be randomized in a 1:1 ratio to receive within 3 hours of last known well time either 1) one dose of IV alteplase and one dose of oral aspirin placebo or 2) one dose of IV alteplase placebo and one dose of oral aspirin 325 milligrams (mg).
Interventions
- DRUG Aspirin
- DRUG Alteplase
- DRUG Aspirin Placebo
- DRUG Alteplase Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2014-05-31 |
| Est. Completion | 2017-03-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02072226
The ClinicalTrials.gov registry entry for NCT02072226 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Aspirin is the first listed.
NCT02072226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02072226 about?
NCT02072226 is a clinical study titled "A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke". PRISMS is a double-blind, multicenter, randomized, Phase IIIb study to evaluate the efficacy and safety of intravenous (IV) alteplase in participants with mild acute ischemic strokes that do not appear to be clearly disabling. Participants will be randomized in a 1:1 ratio to receive within 3 hours ...
What is the current status of trial NCT02072226?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 313 participants. The study started on 2014-05-31. Estimated completion is 2017-03-22.
What interventions are being tested in trial NCT02072226?
The interventions under investigation include: Aspirin (DRUG), Alteplase (DRUG), Aspirin Placebo (DRUG), Alteplase Placebo (DRUG).
Who is sponsoring clinical trial NCT02072226?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.